This trial is active, not recruiting.

Condition retinitis pigmentosa
Treatment anterior chamber (ac) tap
Sponsor Johns Hopkins University
Start date September 2013
End date September 2018
Trial size 100 participants
Trial identifier NCT01949623, BIRP


In this study, markers of oxidative stress will be measured in the aqueous humour and plasma of RP patients compared to controls.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Retinitis Pigmentosa patients
anterior chamber (ac) tap
Aqueous Samples will be collected for measurement of biomarkers
Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
anterior chamber (ac) tap
Aqueous Samples will be collected for measurement of biomarkers

Primary Outcomes

Aqueous levels of markers of oxidative stress in patients with RP and controls.
time frame: 2 years

Eligibility Criteria

Male or female participants from 18 years up to 100 years old.

Inclusion Criteria: - Signed informed consent and authorization of use and disclosure of protected health information - Age more than or equal to 18 years - For the study group, patients diagnosed with Retinitis Pigmentosa by the investigators - For the control group, patients undergoing vitreoretinal surgery for macular hole, epiretinal membrane, vitreomacular traction, retinal detachment, neovascular AMD and Diabetic Retinopathy will be eligible Exclusion Criteria: - Patients with active or suspected ocular or periocular infection

Additional Information

Official title Biomarkers In Retinitis Pigmentosa (BIRP)
Principal investigator Peter Campochiaro, MD
Description People with Retinitis Pigmentosa have loss of night vision followed by loss of central vision due to damage and death of photoreceptors. One of the mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific biomarkers which can be measured. In this study, these biomarkers will be assessed in people with Retinitis Pigmentosa and compared to controls.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Johns Hopkins University.